カテゴリ： Allied Market Research, 世界, 医療/バイオ

がん幹細胞のグローバル市場（2020～2030）：乳房、血液、肺、脳、結腸直腸、膵臓、膀胱、肝臓、その他

■ 英語タイトル：Cancer Stem Cells Market By Cancer Forms (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Others), By Application (Trageted Cancerous Stem Cells, Stem Cell-based cancer Therapy): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23JN086）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23JN086
■ 発行日：2022年9月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：200
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥535,500見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥859,500見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,440,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[がん幹細胞のグローバル市場（2020～2030）：乳房、血液、肺、脳、結腸直腸、膵臓、膀胱、肝臓、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本レポートでは、2021年に1,055.2百万ドルであった世界のがん幹細胞市場規模が2031年には2,711.8百万ドルに達し、2022年から2031年にかけて年平均10.0％成長すると予測しています。Allied Market Research社の本レポートでは、世界のがん幹細胞市場について幅広く調査し、イントロダクション、エグゼクティブサマリー、市場概要、がん形態別分析（乳房、血液、肺、脳、その他）、用途別分析（癌性幹細胞、幹細胞ベースがん治療）、地域別分析（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）、企業状況、企業情報など、以下の内容を掲載しています。さらに、Thermo Fisher Scientific Inc.、AbbVie Inc.、Miltenyi Biotec、STEMCELL Technologies Inc.、Merck KGaA、Stemline Therapeutics, Inc.、MacroGenics, Inc.、Bionomics、FUJIFILM Irvine Scientific.、Lineage Cell Therapeutics, Inc.などの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のがん幹細胞市場規模：がん形態別分析
- 乳房がん幹細胞の市場規模
- 血液がん幹細胞の市場規模
- 肺がん幹細胞の市場規模
- 脳がん幹細胞の市場規模
- その他がん幹細胞の市場規模
・世界のがん幹細胞市場規模：用途別分析
- 癌性幹細胞における市場規模
- 幹細胞ベースがん治療における市場規模
・世界のがん幹細胞市場規模：地域別分析
- 北米のがん幹細胞市場規模
- ヨーロッパのがん幹細胞市場規模
- アジア太平洋のがん幹細胞市場規模
- 中南米/中東・アフリカのがん幹細胞市場規模
・企業状況
・企業情報

世界のがん幹細胞市場は、2022年から2031年にかけて年平均成長率10.0%で拡大するとみられ、2021年に10億5,520万ドル、2031年には27億1,180万ドルに達すると想定されています。
がんは、人間の生命に大きな脅威をもたらす時間的な病気です。がんの治療には、手術、化学療法、放射線療法、標的療法など、さまざまな方法が開発されています。これらの治療法のおかげで、がんの罹患率は女性では横ばい、男性ではやや減少し、がんによる死亡率も同じ期間で減少しています。特定の悪性腫瘍にしか効かない従来のがん治療、転移、不均一性、化学療法や放射線療法に対する抵抗性、免疫学的監視の回避などが、がん治療の失敗の主な原因です。がん幹細胞の特徴が、これらすべての失敗の原因である可能性があります。がん幹細胞は初期段階で停止する能力があり、その結果、新鮮な腫瘍が形成されるため、がんの広がり、がんの再発、多剤耐性、放射線耐性を引き起こす可能性があります。したがって、がん幹細胞は、最も有望ながんの有効な治療法であると考えられます。

幹細胞移植は、悪性腫瘍の診断に用いられる放射線療法を含め、複雑でリスクの高い臨床処置です。がん幹細胞（CSC）と通常の幹細胞は、多くの基本的な生物学的シグナル伝達経路を共有しています。正常な幹細胞は、その微小環境がネガティブに変化するとCSCになる可能性があり、その結果、完全な腫瘍組織が形成されます。移植前の培養中に、移植された幹細胞はゲノム発現や将来の表現型を変化させる環境因子にさらされる可能性があります。幹細胞は培養時間が長くなるにつれて癌化しやすくなります。これらの要因は、予測期間中のがん幹細胞市場の成長を妨げると予測されます。

がん幹細胞は、がん細胞の再発や転移の原因の一つです。がん幹細胞は、化学療法の大部分に耐性があります。さらに、がん幹細胞は腫瘍細胞の不均一性や再発の一因にもなっています。腫瘍の完全な退縮を達成するためには、癌幹細胞に対処しなければなりません。最近の免疫療法の発展は、癌の治療において有望な結果を示しており、それは癌幹細胞にも適用可能です。様々な腫瘍に存在する癌幹細胞は、免疫学的マーカーを発現し、ある種の免疫特性を示しており、腫瘍微小環境に存在する癌幹細胞を標的とする免疫療法に利用することができます。がん幹細胞は最近、技術的進歩や研究開発（R&D）の取り組みにおいて大きな注目を集めています。樹状細胞（DC）ベースのワクチン、適応性T細胞、オンコリティックウイルス、免疫チェックポイント阻害剤、併用療法などを用いて、がん幹細胞を標的とする動きが活発化しています。
COVID-19のパンデミックは、世界中のさまざまなビジネスが停止し、深刻な経済的損失につながるいくつかの不確実性をもたらしました。COVID-19の流行は癌幹細胞市場の成長に大きな影響を与えました。世界的ながん患者の増加により、有効ながん幹細胞治療の必要性が高まっています。がん幹細胞の研究者たちは、COVID-19の大流行時に高まるがん細胞治療への需要に対応するため、様々な政府機関とともに細胞ベースの治療法の研究開発活動に大規模な投資を行っています。例えば、COVID-19パンデミックの間、COVID-19パンデミックに対する抵抗力のための幹細胞の適用性の使用が研究されています。

本レポートに掲載されている主要企業は、AdnaGen GmbH、Advanced Cell Diagnostics, Inc.、AVIVA Biosciences Corporation、Celula, Inc.、Epic Sciences, Inc.、Fluxion Biosciences, Inc.、Rarecells USA, Inc.、Silicon Biosystems, S.p.A.などです。

〈主要市場セグメント〉
がん形態別
乳がん
血液
肺
脳
大腸
膵臓
膀胱
肝臓
その他

用途別
標的がん幹細胞
幹細胞ベースがん治療

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
イギリス
フランス
スペイン
イタリア
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
アラブ首長国連邦
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Thermo Fisher Scientific Inc.
AbbVie Inc.
Miltenyi Biotec
STEMCELL Technologies Inc.
Merck KGaA
Stemline Therapeutics, Inc.
MacroGenics, Inc.
Bionomics
FUJIFILM Irvine Scientific.
Lineage Cell Therapeutics, Inc.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Regulatory Guidelines
3.8.Value Chain Analysis
3.9.Market Share Analysis
3.10.Key Regulation Analysis
3.11.Patent Landscape
CHAPTER 4: CANCER STEM CELLS MARKET, BY CANCER FORMS
4.1 Overview
4.1.1 Market size and forecast
4.2 Breast
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Blood
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Lung
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Brain
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Colorectal
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Pancreatic
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
4.8 Bladder
4.8.1 Key market trends, growth factors and opportunities
4.8.2 Market size and forecast, by region
4.8.3 Market analysis by country
4.9 Liver
4.9.1 Key market trends, growth factors and opportunities
4.9.2 Market size and forecast, by region
4.9.3 Market analysis by country
5.0 Others
5.0.1 Key market trends, growth factors and opportunities
5.0.2 Market size and forecast, by region
5.0.3 Market analysis by country
CHAPTER 5: CANCER STEM CELLS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Trageted Cancerous Stem Cells
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Stem Cell-based cancer Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: CANCER STEM CELLS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Cancer Forms
6.2.3 North America Market size and forecast, by Application
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Cancer Forms
6.2.4.1.2 Market size and forecast, by Application
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Cancer Forms
6.2.4.2.2 Market size and forecast, by Application
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Cancer Forms
6.2.4.3.2 Market size and forecast, by Application
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Cancer Forms
6.3.3 Europe Market size and forecast, by Application
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Cancer Forms
6.3.4.1.2 Market size and forecast, by Application
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Cancer Forms
6.3.4.2.2 Market size and forecast, by Application
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Cancer Forms
6.3.4.3.2 Market size and forecast, by Application
6.3.4.4 Spain
6.3.4.4.1 Market size and forecast, by Cancer Forms
6.3.4.4.2 Market size and forecast, by Application
6.3.4.5 Italy
6.3.4.5.1 Market size and forecast, by Cancer Forms
6.3.4.5.2 Market size and forecast, by Application
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Cancer Forms
6.3.4.6.2 Market size and forecast, by Application
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Cancer Forms
6.4.3 Asia-Pacific Market size and forecast, by Application
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Cancer Forms
6.4.4.1.2 Market size and forecast, by Application
6.4.4.2 Japan
6.4.4.2.1 Market size and forecast, by Cancer Forms
6.4.4.2.2 Market size and forecast, by Application
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Cancer Forms
6.4.4.3.2 Market size and forecast, by Application
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Cancer Forms
6.4.4.4.2 Market size and forecast, by Application
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Cancer Forms
6.4.4.5.2 Market size and forecast, by Application
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Cancer Forms
6.4.4.6.2 Market size and forecast, by Application
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Cancer Forms
6.5.3 LAMEA Market size and forecast, by Application
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Cancer Forms
6.5.4.1.2 Market size and forecast, by Application
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Cancer Forms
6.5.4.2.2 Market size and forecast, by Application
6.5.4.3 UAE
6.5.4.3.1 Market size and forecast, by Cancer Forms
6.5.4.3.2 Market size and forecast, by Application
6.5.4.4 South Africa
6.5.4.4.1 Market size and forecast, by Cancer Forms
6.5.4.4.2 Market size and forecast, by Application
6.5.4.5 Rest of LAMEA
6.5.4.5.1 Market size and forecast, by Cancer Forms
6.5.4.5.2 Market size and forecast, by Application
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Thermo Fisher Scientific Inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 AbbVie Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Miltenyi Biotec
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 STEMCELL Technologies Inc.
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Merck KGaA
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Stemline Therapeutics, Inc.
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 MacroGenics, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Bionomics
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 FUJIFILM Irvine Scientific.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Lineage Cell Therapeutics, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 2. CANCER STEM CELLS MARKET SIZE, FOR BREAST, BY REGION, 2021-2031 ($MILLION)
TABLE 3. CANCER STEM CELLS MARKET FOR BREAST, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. CANCER STEM CELLS MARKET SIZE, FOR BLOOD, BY REGION, 2021-2031 ($MILLION)
TABLE 5. CANCER STEM CELLS MARKET FOR BLOOD, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. CANCER STEM CELLS MARKET SIZE, FOR LUNG, BY REGION, 2021-2031 ($MILLION)
TABLE 7. CANCER STEM CELLS MARKET FOR LUNG, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. CANCER STEM CELLS MARKET SIZE, FOR BRAIN, BY REGION, 2021-2031 ($MILLION)
TABLE 9. CANCER STEM CELLS MARKET FOR BRAIN, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. CANCER STEM CELLS MARKET SIZE, FOR COLORECTAL, BY REGION, 2021-2031 ($MILLION)
TABLE 11. CANCER STEM CELLS MARKET FOR COLORECTAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. CANCER STEM CELLS MARKET SIZE, FOR PANCREATIC, BY REGION, 2021-2031 ($MILLION)
TABLE 13. CANCER STEM CELLS MARKET FOR PANCREATIC, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. CANCER STEM CELLS MARKET SIZE, FOR BLADDER, BY REGION, 2021-2031 ($MILLION)
TABLE 15. CANCER STEM CELLS MARKET FOR BLADDER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. CANCER STEM CELLS MARKET SIZE, FOR LIVER, BY REGION, 2021-2031 ($MILLION)
TABLE 17. CANCER STEM CELLS MARKET FOR LIVER, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. CANCER STEM CELLS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. CANCER STEM CELLS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. GLOBAL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 21. CANCER STEM CELLS MARKET SIZE, FOR TRAGETED CANCEROUS STEM CELLS, BY REGION, 2021-2031 ($MILLION)
TABLE 22. CANCER STEM CELLS MARKET FOR TRAGETED CANCEROUS STEM CELLS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. CANCER STEM CELLS MARKET SIZE, FOR STEM CELL-BASED CANCER THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 24. CANCER STEM CELLS MARKET FOR STEM CELL-BASED CANCER THERAPY, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. CANCER STEM CELLS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. U.S. CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 30. U.S. CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 31. CANADA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 32. CANADA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 33. MEXICO CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 34. MEXICO CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 35. EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 36. EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 37. EUROPE CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 38. GERMANY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 39. GERMANY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 40. UNITED KINGDOM CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 41. UNITED KINGDOM CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 42. FRANCE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 43. FRANCE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 44. SPAIN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 45. SPAIN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 46. ITALY CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 47. ITALY CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 49. REST OF EUROPE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. CHINA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 54. CHINA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 55. JAPAN CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 56. JAPAN CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 57. INDIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 58. INDIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 59. SOUTH KOREA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 60. SOUTH KOREA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 61. AUSTRALIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 63. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 64. REST OF ASIA PACIFIC CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 65. LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 66. LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 67. LAMEA CANCER STEM CELLS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 68. BRAZIL CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 69. BRAZIL CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 70. SAUDI ARABIA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 71. SAUDI ARABIA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 72. UAE CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 73. UAE CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 74. SOUTH AFRICA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 75. SOUTH AFRICA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 76. REST OF LAMEA CANCER STEM CELLS MARKET, BY CANCER FORMS, 2021-2031 ($MILLION)
TABLE 77. REST OF LAMEA CANCER STEM CELLS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
TABLE 78.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 79.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
TABLE 80.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 81.THERMO FISHER SCIENTIFIC INC.: NET SALES,
TABLE 82.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
TABLE 83.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 84.ABBVIE INC.: OPERATING SEGMENTS
TABLE 85.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 86.ABBVIE INC.: NET SALES,
TABLE 87.ABBVIE INC.: KEY STRATERGIES
TABLE 88.MILTENYI BIOTEC: COMPANY SNAPSHOT
TABLE 89.MILTENYI BIOTEC: OPERATING SEGMENTS
TABLE 90.MILTENYI BIOTEC: PRODUCT PORTFOLIO
TABLE 91.MILTENYI BIOTEC: NET SALES,
TABLE 92.MILTENYI BIOTEC: KEY STRATERGIES
TABLE 93.STEMCELL TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 94.STEMCELL TECHNOLOGIES INC.: OPERATING SEGMENTS
TABLE 95.STEMCELL TECHNOLOGIES INC.: PRODUCT PORTFOLIO
TABLE 96.STEMCELL TECHNOLOGIES INC.: NET SALES,
TABLE 97.STEMCELL TECHNOLOGIES INC.: KEY STRATERGIES
TABLE 98.MERCK KGAA: COMPANY SNAPSHOT
TABLE 99.MERCK KGAA: OPERATING SEGMENTS
TABLE 100.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 101.MERCK KGAA: NET SALES,
TABLE 102.MERCK KGAA: KEY STRATERGIES
TABLE 103.STEMLINE THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 104.STEMLINE THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 105.STEMLINE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 106.STEMLINE THERAPEUTICS, INC.: NET SALES,
TABLE 107.STEMLINE THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 108.MACROGENICS, INC.: COMPANY SNAPSHOT
TABLE 109.MACROGENICS, INC.: OPERATING SEGMENTS
TABLE 110.MACROGENICS, INC.: PRODUCT PORTFOLIO
TABLE 111.MACROGENICS, INC.: NET SALES,
TABLE 112.MACROGENICS, INC.: KEY STRATERGIES
TABLE 113.BIONOMICS: COMPANY SNAPSHOT
TABLE 114.BIONOMICS: OPERATING SEGMENTS
TABLE 115.BIONOMICS: PRODUCT PORTFOLIO
TABLE 116.BIONOMICS: NET SALES,
TABLE 117.BIONOMICS: KEY STRATERGIES
TABLE 118.FUJIFILM IRVINE SCIENTIFIC.: COMPANY SNAPSHOT
TABLE 119.FUJIFILM IRVINE SCIENTIFIC.: OPERATING SEGMENTS
TABLE 120.FUJIFILM IRVINE SCIENTIFIC.: PRODUCT PORTFOLIO
TABLE 121.FUJIFILM IRVINE SCIENTIFIC.: NET SALES,
TABLE 122.FUJIFILM IRVINE SCIENTIFIC.: KEY STRATERGIES
TABLE 123.LINEAGE CELL THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 124.LINEAGE CELL THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 125.LINEAGE CELL THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 126.LINEAGE CELL THERAPEUTICS, INC.: NET SALES,
TABLE 127.LINEAGE CELL THERAPEUTICS, INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

※関連データはありません。

※注目の調査資料
 ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(ALD23JN086 )"がん幹細胞のグローバル市場（2020～2030）：乳房、血液、肺、脳、結腸直腸、膵臓、膀胱、肝臓、その他" (英文：Cancer Stem Cells Market By Cancer Forms (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver, Others), By Application (Trageted Cancerous Stem Cells, Stem Cell-based cancer Therapy): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

◆H&Iグローバルリサーチのお客様（例）◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。